Source comparison
MK-677 Safety Profile: Dosing Strategy Comparison
Different dosing strategies produce distinct safety and efficacy trade-offs. The table below compares outcomes from published trials and research applications: 10mg daily +40–50% above baseline ~30% report increased hunger Minimal; <1kg fluid gain in most subj
This comparison does not assign a generated winner or score.
- Different dosing strategies produce distinct safety and efficacy trade-offs. The table below compares outcomes from published trials and research applications:
- 10mg daily
- +40–50% above baseline
- ~30% report increased hunger
- Minimal; <1kg fluid gain in most subjects
- Fasting glucose +2–4 mg/dL; rarely clinically significant
- Best for protocols prioritizing minimal confounding variables; lower efficacy ceiling
- 25mg daily (standard)
- +60–90% above baseline
- 50–60% report increased hunger
- Moderate; 2–4kg fluid gain, peaks weeks 2–4
- Fasting glucose +5–8 mg/dL; HbA1c +0.3–0.5%
- Gold standard dose in clinical trials; optimal efficacy-to-safety ratio for most research
- 50mg daily
- +80–100% above baseline (diminishing returns)
- >70% report increased hunger
- Pronounced; >4kg in some subjects
- Fasting glucose +8–12 mg/dL; insulin resistance markers elevated
- Higher adverse event rate without proportional efficacy gain; rarely justified
- Intermittent (5 days on / 2 days off)
- +50–70% average; fluctuates weekly
- Variable; hunger peaks on dosing days
- Reduced compared to continuous; ~1–2kg
- Intermediate; glucose rises on dosing days, normalizes on off days
- Emerging strategy in longevity research; may reduce metabolic adaptation
- Pulsed (2 weeks on / 2 weeks off)
- Cyclic; returns near baseline during off weeks
- Resolves completely during washout
- Fully reversible during off periods
- Used in body composition studies to isolate anabolic phase effects; safety profile identical to continuous during 'on' weeks
- The professional consensus: 25mg daily remains the evidence-backed dosing standard. Lower doses reduce side effect frequency but sacrifice efficacy. Higher doses amplify adverse events without meaningful outcome improvements. Intermittent and pulsed protocols offer theoretical advantages. Reduced receptor desensitization, lower cumulative metabolic stress. But lack the long-term safety data available for continuous dosing.